Empiric combination therapy for gram-negative bacteremia

Pediatrics

Volumn 133, Issue 5, 2014, Pages

  Sick, Anna C ^a   Tschudin Sutter, Sarah ^b   Turnbull, Alison E ^c   Weissman, Scott J ^d   Tamma, Pranita D ^e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aminoglycoside; B lactam; Combination therapy; Empiric therapy; Gram negative bacteremia

Indexed keywords

AMINOGLYCOSIDE; AZTREONAM; BETA LACTAM; CARBAPENEM; CEFEPIME; CEFTRIAXONE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT;

ADOLESCENT; ANTIBACTERIAL ACTIVITY; ARTICLE; CHILD; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; DISEASE DURATION; DISEASE SEVERITY; DRUG POTENTIATION; GRAM NEGATIVE SEPSIS; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL FACTOR; TREATMENT INDICATION; BACTEREMIA; COHORT ANALYSIS; DRUG COMBINATION; EMPIRICISM; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; INFANT; KAPLAN MEIER METHOD; MALE; OPPORTUNISTIC INFECTIONS; PRESCHOOL CHILD; PROPENSITY SCORE; RADIATION RESPONSE; RISK; SURVIVAL; UNITED STATES;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTEREMIA; BALTIMORE; BETA-LACTAMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; EMPIRICISM; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; NEUTROPENIA; ODDS RATIO; OPPORTUNISTIC INFECTIONS; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84899806095     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-3363     Document Type: Article

References (31)

1. Düzova A, Kutluk T, Kanra G, et al. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. Turk J Pediatr. 2001;43(2):105-109
2. Advani S, Reich NG, Sengupta A, Gosey L, Milstone AM. Central line-associated bloodstream infection in hospitalized children with peripherally inserted central venous catheters: extending risk analyses outside the intensive care unit. Clin Infect Dis. 2011;52 (9):1108-1115
3. Tamma PD, Turnbull AE, Harris AD, Milstone AM, Hsu AJ, Cosgrove SE. Less is more: combination antibiotic therapy for the treatment of gram-negative bacteremia in pediatric patients. JAMA Pediatr. 2013;167 (10):903-910
4. Paul M, Leibovici L. Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses. Infect Dis Clin North Am. 2009;23(2):277- 293
5. Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev. 2006; (1): CD003344
6. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012;25(3):450-470
7. Kumar A, Zarychanski R, Light B, et al; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensitymatched analysis. Crit Care Med. 2010;38 (9):1773-1785
8. Pereira CA, Petrilli AS, Carlesse FA, Luisi FA, da Silva KV, de Martino Lee ML. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison. J Microbiol Immunol Infect 2009;42(2):141-147
9. Yildirim I, Aytac S, Ceyhan M, et al. Piperacillin/ tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies. Pediatr Hematol Oncol. 2008; 25(4):291-299
10. Zengin E, Sarper N, Kiliç SC. Piperacillin/ tazobactam monotherapy versus piperacillin/ tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia. Pediatr Hematol Oncol. 2011;28(4):311-320
11. Aksoylar S, Cetingül N, Kantar M, Karapinar D, Kavakli K, Kansoy S. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children. Pediatr Hematol Oncol. 2004;21(2):115-123
12. Hung KC, Chiu HH, Tseng YC, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy. J Microbiol Immunol Infect. 2003;36(4):254-259
13. Petrilli AS, Cypriano M, Dantas LS, et al. Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma. Brazil J Infect Dis 2003;7(2):111-120
14. Fleischhack G, Schmidt-Niemann M, Wulff B, et al. Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients. Support Care Cancer 2001;9(5):372-379
15. Snelling S, Hart CA, Cooke RW. Ceftazidime or gentamicin plus benzylpenicillin in neonates less than forty-eight hours old. J Antimicrob Chemother. 1983;12(suppl A): 353-356
16. Miall-Allen VM, Whitelaw AG, Darrell JH. Ticarcillin plus clavulanic acid (Timentin) compared with standard antibiotic regimes in the treatment of early and late neonatal infections. Br J Clin Pract. 1988;42(7):273-279
17. Custer JW, Rau RE. The Harriet Lane Handbook. 18th ed. Philadelphia: Mosby- Elsevier; 2009
18. Johns Hopkins Medicine. Available at: www. insidehopkinsmedicine.org/amp/ pediatrics/ downloads/Aminoglycoside-Guidelines.pdf. Accessed February 19, 2014
19. Johns Hopkins Medicine. Available at: www. insidehopkinsmedicine.org/amp/ pediatrics/ downloads/CA-BSI-Guidelines.pdf. Accessed February 19, 2014
20. Park SH, Milstone AM, Diener-West M, Nussenblatt V, Cosgrove SE, Tamma PD. Short versus prolonged courses of antibiotic therapy for children with uncomplicated Gram-negative bacteraemia. J Antimicrob Chemother. 2013; (Oct):24
21. Tamma PD, Girdwood SC, Gopaul R, et al. The use of cefepime for treating AmpC b-lactamase-producing Enterobacteriaceae. Clin Infect Dis. 2013;57(6):781-788
22. Tamma PD, Turnbull AE, Milstone AM, Lehmann CU, Sydnor ER, Cosgrove SE. Ventilator-associated tracheitis in children: does antibiotic duration matter? Clin Infect Dis. 2011;52(11):1324-1331
23. Centers for Disease Control and Prevention. Available at: www.cdc.gov/hai/settings/ lab/lab-esbl.html. Accessed February 19, 2014
24. The Centers for Disease Control and Prevention. Available at: www.ndhealth.gov/ microlab/Uploads/HodgeTest.pdf. Accessed February 19, 2014
25. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. Available at: www.R-project.org/
26. Tamma PD, Robinson GL, Gerber JS, et al. Pediatric antimicrobial susceptibility trends across the United States. Infect Control Hosp Epidemiol. 2013;34(12):1244-1251
27. Bhat S, Fujitani S, Potoski BA, et al. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved? Int J Antimicrob Agents. 2007;30 (5):458-462
28. Drinka P, Niederman MS, El-Solh AA, Crnich CJ. Assessment of risk factors for multidrug resistant organisms to guide empiric antibiotic selection in long term care: a dilemma. J Am Med Dir Assoc. 2011;12(5): 321-325
29. Bowers DR, Liew YX, Lye DC, Kwa AL, Hsu LY, Tam VH. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2013;57(3): 1270-1274
30. Martínez JA, Cobos-Trigueros N, Soriano A, et al. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother. 2010;54(9): 3590-3596
31. Jenh AM, Tamma PD, Milstone AM. Extended-interval aminoglycoside dosing in pediatrics. Pediatr Infect Dis J. 2011;30(4): 338-339